Form 4: BDX EVP Sells Shares Under 10b5-1 Plan

Becton Dickinson's EVP, Chief Revenue Officer Michael Feld, sold 75 shares of common stock for $181.84 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Feld, EVP, Chief Revenue Officer of Becton Dickinson & Co (BDX), sold 75 shares of common stock.
• The transaction occurred on February 26, 2026, at a price of $181.84 per share.
• Following this sale, Michael Feld beneficially owns 21,308 shares of BDX common stock directly.
• The sale was executed under a Rule 10b5-1 trading plan adopted by Mr. Feld on February 7, 2025.
• Direct holdings reflect adjustments related to the combination of Biosciences and Diagnostic Solutions businesses with Waters Corp., impacting previously reported and unvested time-vested restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It's a routine insider sale under a pre-arranged plan, which typically does not convey significant positive or negative signals about the company's operational performance or future prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned transaction rather than an immediate reaction to new information.
• The number of shares sold (75) is a relatively small fraction of the total beneficial ownership (21,308 shares), suggesting no significant reduction in insider exposure.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common in the medical technology and healthcare sectors, often occurring under pre-arranged 10b5-1 plans for personal financial planning. The mention of adjustments related to a business combination (Biosciences and Diagnostic Solutions with Waters Corp.) highlights ongoing strategic realignments within the industry, which can impact executive compensation structures and equity holdings.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice for executives to manage their equity holdings while avoiding accusations of trading on material non-public information. This aligns with corporate governance best practices seen in companies like Johnson & Johnson (JNJ) or Medtronic (MDT), where executives routinely use such plans for diversification or liquidity.
• The relatively small number of shares sold (75 shares) compared to the remaining beneficial ownership (21,308 shares) is typical for routine personal financial planning, rather than a significant divestment that might signal a lack of confidence in the company's future. For example, a CEO selling 0.5% of their holdings is less impactful than selling 50%.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the sale as a minor reduction in insider alignment, though mitigated by the 10b5-1 plan. The small volume suggests minimal impact on market sentiment.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale under a pre-arranged 10b5-1 plan, involving a small number of shares relative to the executive's total holdings. Such transactions are typically for personal financial management and do not provide new material information about the company's operational performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Becton Dickinson, BDX, Michael Feld, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Medical Technology, Healthcare